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Abstract:  
Patients with hypertension (high blood pressure) have increased risk for cardiovascular 
diseases, stroke, myocardial infarction, diabetes, and kidney failure. Only 51.8% of 
hypertensive patients have their blood pressure (BP) under control, and control is 
difficult to achieve since so little is known about the molecular and genetic regulation of 
BP. A thorough understanding of the pathways that regulate BP can lead to more 
effective and personalized antihypertensive therapies. We previously established that a 
protein called GTPase Regulator Associated with Focal adhesion kinase 3 (GRAF3) 
helps maintain normal BP by inhibiting RhoA in smooth muscle cells (SMCs). This in 
turn reduces the SMC contractility and BP. Two previous genome wide association 
studies for BP and cardiovascular disease identified two single nucleotide 
polymorphisms (SNPs) within the first intron of the GRAF3 gene, rs633185 and 
rs604723, which are associated with a 2 mm Hg increase in BP in humans. I performed 
an allelic discrimination assay on rs604723 and found that this SNP is more prevalent in 
non-hypertensive individuals. Additionally, the population homozygous for this SNP has 
the lowest average systolic blood pressure (126.29 mm Hg) and diastolic blood 
pressure (76.87 mm Hg). It is also known that risk associated with hypertension varies 
in different race groups. Our study shows that the minor allele frequency of SNP 
rs604723 is higher in Caucasians (26.74%) than in African Americans (4.84%). These 
results provide support for the hypothesis that SNP rs604723 plays a protective role in 
BP regulation. Future analysis will be aimed at studying SNP rs604723 and other SNPs 
in the RhoA pathway in more detail, in hopes of someday developing better 
antihypertensive therapies. 
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Introduction: 
            Blood pressure (BP) is a very complex trait that is not regulated by one specific 
organ system or one signaling pathway. It is under the control of multiple organ systems 
such as the endocrine, nervous, cardiovascular, and urinary systems. Patients with high 
BP, which is known as hypertension (HTN), have a higher risk for cardiovascular 
diseases, stroke, myocardial infarction, diabetes, and kidney failure. Even though 1 of 3 
US adults has HTN and only 51.8% have their BP under control1, very little is known 
about its regulation at the molecular level and what genes and mechanisms are 
involved. Therefore, a thorough understanding of the molecular and genetic pathways 
that regulate blood pressure can lead to more effective and personalized 
antihypertensive therapies. 
         A common characteristic of HTN is increased peripheral vascular resistance due 
to decreased arteriolar vessel diameter. This is a result of increased smooth muscle cell 
(SMC) contractions within resistance arterioles whose internal diameter is less than 200 
microns 2-6. Figure 1 shows a schematic representation of the Ca2+- calmodulin pathway 
and RhoA pathway that regulate SMC contractions and blood pressure. When an 
extracellular vasoconstrictor signal such as angiotensin II, endothelin-1, or 
norepinephrine binds to and activates a G-protein coupled receptor (GPCR) on the cell 
surface of a SMC, the GPCR activates the intracellular Ca2+- calmodulin pathway. This 
pathway eventually activates myosin light chain (MLC) protein, which then associates 
with actin and lead to SMC contraction 7,8. Increasing SMC contraction increases 
vascular resistance due to vasoconstriction, resulting in an increase in blood pressure. 
Simultaneously, the binding of extracellular signals to GPCR also triggers the guanine 
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nucleotide exchange factors (GEFs) to activate RhoA, a GTP-binding protein, in the 
SMCs. This activated RhoA activates Rho-
kinase (ROCK) whose function is to inhibit 
myosin phosphatase from dephosphorylating 
MLC 9-12. Consequently, MLC remains 
phosphorylated and activated which results in 
more SMC contraction. Indeed, increased 
ROCK activity has been observed in 
hypertensive rats and some hypertensive 
patient populations 9,13 while ROCK inhibitors 
have led to reduced blood pressure in 
hypertensive animal models and patients 14. Therefore, RhoA has been implicated in 
vasoconstrictor-induced hypertension. 
         Once activated, RhoA has intrinsic GTP-hydrolyzing (GTPase) activity, and it 
becomes inactivated by hydrolyzing its bound GTP to GDP. The GTPase-activating 
proteins (GAPs) promote the GTP hydrolysis. Therefore, proper activity of the RhoA-
specific GAPs is required to keep RhoA and ROCK activity in control, which in turn can 
keep SMC contraction and blood pressure in control. Our lab has identified GTPase 
regulator associated with focal adhesion kinase 3 (GRAF3) to be a RhoA-specific GAP. 
Immunohistochemical analysis of mouse and human tissues with a GRAF3 antibody 
showed that GRAF3 gene is selectively expressed in the SMCs15. Thus, the lab 
reasoned that GRAF3 might play an important role in regulating SMC contractions and 
BP.  
Figure 1: A schematic representation of SMC 
contractility and blood pressure regulation by the 
Ca2+ - calmodulin pathway and RhoA pathway 
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         In order to test the association between GRAF3 gene and blood pressure, the lab 
had knocked down the GRAF3 gene via a gene-trap in mice. In a gene-trap mouse, a 
gene-trap cassette is genetically engineered in the gene of interest, which results in 
alternative splicing of the mRNA and translation of a dysfunctional, truncated protein. 
When GRAF3 is knocked down in this manner, a significant increase in BP is observed 
in the mice 15. Specifically, homozygous gene-trap mice showed higher BP than 
heterozygous gene-trap mice. This indicates the dose dependent phenotype of GRAF3. 
Furthermore, GRAF3-deficient SMCs have increased levels of MLC phosphorylation 
and RhoA activity. The GRAF3 gene can be returned to its original state by using Cre-
Lox recombination. Cre-recombinase removes the gene trap cassette, which has been 
flanked by Lox P sites. When GRAF3 gene is reintroduced only in SMC, by crossing 
GRAF3 gene trap mice in SMMHC-Cre ERT2 mice, BP returns back to normal. Hence, 
all these results indicate that GRAF3 helps maintain normal BP by inhibiting RhoA 
activity in SMC, which in turn reduces the SMC contractility and BP 15. 
         After establishing the fact that GRAF3 gene plays a role in controlling SMC 
contraction and thus BP, the next step is to identify how the function of GRAF3 can be 
compromised. Two previous genome wide association studies have identified a novel 
BP associated locus containing two single nucleotide polymorphisms (SNPs) in perfect 
linkage disequilibrium (rs633185 and rs604723) within the first intron of GRAF3 
gene16,17. This means that a statistical non-random association between these two 
SNPs have been found. Both these SNPs are located in DNase hypersensitivity sites 
(DHS), which are specific regions of the genome where the chromatin is not in its 
condensed form, making the DNA more accessible for transcription. Since there is 
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“open” chromatin, active transcription takes place at these sites. These SNPs are also 
associated with a significant reduction in BP with each copy of the minor allele. Thus, 
the lab has hypothesized that these SNPs play a protective role in regulation of BP. 
However, when the lab cloned both the SNP containing segments into luciferase 
vectors and tested protein expression, the differing alleles of rs604723 showed 
differences in expression, whereas the differing alleles of rs633185 showed no 
differences. Therefore, the SNP rs604723 was chosen for further research. Specifically, 
my research project focused on determining whether the SNP rs604273 is correlative 
with HTN and whether it is more frequent in people of a particular race since it is known 
that risk associated with hypertension varies in different races.  
Methods:  
Allelic Discrimination Assay 
The Applied Biosystems 7500 Fast Reverse Transcription Polymerase Chain Reaction 
(RT PCR) machine was used to perform a Taqman Allelic Discrimination Assay for the 
SNP rs604723 on 510 human gDNA samples, obtained from the Heart Healthy Lenoir 
Study. Allelic Discrimination Assay is a PCR-based assay that genotypes the two 
possible variants at the SNP site in the target template sequence by measuring 
fluorescence signals and using two SNP variant specific probes. For SNP rs604273, the 
major allele is the nucleotide C at the SNP site, and the minor allele is the nucleotide T 
at the SNP site. Furthermore, the SNP probe for the nucleotide C is attached to a 
fluorescent FAM dye, and the SNP probe for the nucleotide T is attached to a 
fluorescent VIC dye. When a SNP probe matches with its complementary sequence, the 
fluorophore is cleaved, and the fluorescent signal is measured by the machine. Table 1 
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shows the association between the fluorescence signal levels and the corresponding 
genotype of SNP rs604723 in the 510 human gDNA samples.  
 
Table 1: Determination of the sequence’s genotype based on fluorescent signal levels 
Fluorescence signal detected Genotype 
VIC dye only Homozygous T/T 
FAM dye only Homozygous C/C 
VIC and FAM dye both Heterozygous C/T 
 
The positive controls for this experiment were pGL3-DHS2T and pGL3-DHS2C, 
which were previously made by the lab. The positive control, pGL3-DHS2T, was made 
by isolating DHS2T from human DNA and putting it into the vector pGL3. DHS2T is the 
DHS where the SNP rs604723 is found with the minor allele T. The second positive 
control, pGL3-DHS2C, was made by performing site-directed mutagenesis on pGL3-
DHS2T. The negative control was water.  
The samples were prepared on 96-well plates, where each reaction well was 
prepared by following the protocol described in Table 2.  
Table 2: Sample Preparation for Allelic Discrimination Assay 
Reagent  Quantity  
Taqman Genotyping MasterMix (20X) 5 𝜇𝐿 
SNP Probe (40X) 0.5 𝜇𝐿 
Wet DNA/control (10 ng/µL) 1 𝜇𝐿 
DEPC-H2O 3.5 𝜇𝐿 
 
 
 
 Doshi 8 
Minor Allele Frequency Calculation 
After genotyping all the samples obtained from the Heart Healthy Lenoir Study, the data 
was combined with the genotype data from two other hypertensive studies: UNC Family 
Medicine Study, a longitudinal study directed by co-PI Dr. Anthony Viera, and CAD, Dr. 
George Stouffer and Dr. Craig Lee’s study. The SNP genotyping assays for rs604723 
were previously performed by the lab for these two studies, and I used the genotype 
data to calculate the Minor Allele Frequency (MAF) of hypertensive vs. non-
hypertensive populations and populations of different races. 
MAF, which is the frequency of the least common allele in a given population, is 
calculated as follows:  
𝑀𝐴𝐹 =  # 𝑜𝑓 𝑠𝑎𝑚𝑝𝑙𝑒𝑠 𝑤𝑖𝑡ℎ 𝑔𝑒𝑛𝑜𝑡𝑦𝑝𝑒 𝑇/𝑇 +  0.5 ∗ # 𝑜𝑓 𝑠𝑎𝑚𝑝𝑙𝑒𝑠 𝑤𝑖𝑡ℎ 𝑔𝑒𝑛𝑜𝑡𝑦𝑝𝑒 𝐶/𝑇𝑇𝑜𝑡𝑎𝑙 # 𝑜𝑓 𝑠𝑎𝑚𝑝𝑙𝑒𝑠  
The statistical analysis on the results obtained was done by a post-doc student’s t-test, 
and the p-values < 0.05 were considered statistically significant. 
Results: 
 To evaluate the presence of the 
SNP rs604723, 510 patient gDNA samples, 
obtained from the Heart Healthy Lenoir 
Study, were genotyped through an allelic 
discrimination assay. The allelic 
discrimination plot for SNP rs604723 of 
GRAF3 gene shows that there were 13 
patients with the genotype T/T, 112 with the 
genotype T/C, and 385 patients with the genotype C/C (Figure 2).  
Figure 2: Allelic Discrimination Plot for SNP 
rs604723 for 510 human cDNA samples obtained 
from Lenoir County Database 
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Previously, the lab had performed an allelic discrimination assay for SNP 
rs604723 on the samples obtained from UNC Family Medicine Study and CAD Study. In 
UNC Family Medicine Study, the blood pressure data for each patient was collected 
during two visits, and the patients were not on any antihypertensive therapy before 
taking part in the study. The patients with systolic blood pressure (SBP) of 140 mm Hg 
and higher in both visits were considered hypertensive. The MAF for the hypertensive 
population was 22.08%, which is lower than the MAF for the non-hypertensive 
population, which was 26.09% (Table 3). However, this dataset does not reach 
statistical significance.   
Furthermore, for the patients of UNC Family Medicine Study, the average SBP 
and diastolic blood pressure (DBP) was compared between patients with different 
genotypes. The patients homozygous for minor allele T had the lowest average SBP, 
126.29 mm Hg versus 129.58 mm Hg in patients homozygous for the major allele C, but 
this difference is not statistically significant (p = 0.199). A more pronounced and 
statistically significant effect was observed when comparing DBP, which averaged 
76.87 mm Hg in patients homozygous for the minor allele T and 81.79 mm Hg in 
patients homozygous for the major allele C (p = 0.028; Table 4).  
Lastly, the genotyping data obtained for the patients of Heart Healthy Lenoir 
Study was combined with the data from UNC Family Medicine Study and CAD Study in 
order to see if MAF of the SNP rs604723 varies between different races. The proportion 
of homozygous subjects in each race group (Caucasian, African American, and Other) 
is significantly different (p < 0.001). The Other race group included patients who 
identified themselves as non-Caucasian and non-African American, and a good majority 
 Doshi 10 
of these patients were of Hispanic descent. Notably, there is a significant decrease in 
the percentage of African Americans that contain the minor T allele (Table 5).  
 
Table 3: Minor Allele Frequency (MAF) for SNP rs604723 is higher in hypertensive 
vs. non-hypertensive patients in the UNC Family Medicine Study. gDNA was 
isolated from patient’s blood and then genotyped using a Taqman SNP genotyping 
assay for rs604723 (n=346). MAF between hypertensive and non-hypertensive patients 
was calculated. Patients were considered hypertensive if the systolic BP was greater 
than 140 for 2 clinic visits. T corresponds to the minor allele and C corresponds to the 
major allele. No statistical significance reached. 
  Genotype frequency Sum Minor Allele 
Frequency 
T/T T/C C/C 
Hypertensive 12 78 141 231 22.08% 
Non-hypertensive 8 44 63 115 26.09% 
 
 
Table 4: There is correlation between blood pressure and genotype of GRAF3 
SNP rs604723 in patients in the UNC Family Medicine Study. gDNA was isolated 
from patient’s blood and then genotyped using a Taqman SNP genotyping assay for 
rs604723 (n = 348 patients). The average SBP and DBP for each of the three 
genotypes were calculated. T corresponds to the minor allele and C corresponds to the 
major allele. The difference in the average SBP between T/T patients and C/C patients 
is not statistically significant (p=0.199), but the difference in the average DBP between 
T/T patients and C/C patients is statistically significant (p=0.028). 
  Genotype Frequency 
  T/T T/C C/C 
Average Systolic Blood Pressure (mm Hg) 126.29 129.03 129.58 
Average Diastolic Blood Pressure (mm Hg) 76.87 81.14 81.79 
Number of Patients 19 123 206 
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Table 5: Minor Allele Frequency (MAF) is greater in Caucasian patients than 
African American patients in the Heart Healthy Lenoir Study, UNC Family 
Medicine Study, and CAD Study. gDNA was isolated from patient’s blood and then 
genotyped using a Taqman SNP genotyping assay for rs604723 (n=505 in the Heart 
Healthy Lenoir Study, n=350 in the UNC Family Medicine Study, n=369 in the CAD 
Study). MAF between patients of different races was calculated. Other race group 
consists of Hispanic patients, and non-Caucasian, non-African American patients. T 
corresponds to the minor allele and C corresponds to the major allele. The proportion of 
homozygous subjects in each race group is significantly different (p<0.001). 
Race Genotype Frequency Sum Minor Allele 
Frequency 
T/T T/C C/C 
Caucasian 47 302 392 741 26.72% 
African American 0 40 390 430 4.65% 
Other 6 21 26 53 31.13% 
 
Discussion: 
The original goal was to combine the genotyping data obtained for the Heart 
Healthy Lenoir Study with data from UNC Family Medicine Study and CAD Study, 
compare the MAF of the SNP rs604723 in hypertensive vs. non-hypertensive 
population, and conclude whether this SNP is more frequent in non-hypertensive 
population. However, as nearly all of the patients in the Heart Healthy Lenoir Study 
were treated with anti-hypertensive medicines prior to our assessment, we are not able 
to use Heart Healthy Lenoir Study’s data to draw conclusions regarding the association 
between the SNP rs604723 and hypertension.  
For the dataset of UNC Family Medicine Study in which all patients were un-
treated at the start of the study, the MAF was higher in non-hypertensive population by 
4.01%, but this dataset does not reach statistical significance (Table 3). This correlation 
when combined with the lab’s studies in mice suggests that the SNP rs604723 may help 
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the non-hypertensive population maintain their BP by protecting GRAF3 gene’s 
function. Furthermore, patients homozygous for the minor allele T had the lowest 
average SBP and DBP among the three genotypic subgroups (Table 4). A statistically 
significant difference in the DBP between patients homozygous for the T allele and 
patients homozygous for the C allele (p=0.028) provided evidence for the hypothetical 
protective role of SNP rs604723 in BP regulation. Next, the prevalence of SNP 
rs604723 in different race populations was analyzed. One significant difference 
observed in the data collected from all the studies – Heart Healthy Lenoir Study, UNC 
Family Medicine Study, and CAD Study – was that the SNP rs604723 is more frequent 
in the Caucasian population than in the African American population (Table 5). If the 
SNP rs604723 does in fact has a protective role of reducing blood pressure by 
increasing more expression of GRAF3, it can help explain why the African American 
population is more prone to have salt sensitivity and HTN 18.  
  Another interesting aspect is that the MAF was highest in the Other race group 
(Table 5). This race group included patients who identified themselves as non-
Caucasian non-African American, and these patients were primarily of Hispanic 
descent. Thus, further analysis is needed to determine which specific race has the 
highest MAF. Also, a bigger sample size, with more detailed race breakdown 
information for the Other race group, is required to get accurate MAF information. 
Therefore, from the data analysis performed so far, trends have been found that 
indicate that SNP rs604723 plays a protective role in BP regulation by increasing 
GRAF3 gene expression. However, a bigger sample size and further analysis of more 
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hypertensive studies that have patients who are un-treated at the time of data collection 
are needed before making a conclusion.  
Given that BP is a highly variable trait, it is possible that there are numerous 
SNPs along the RhoA pathway that correlate with different levels of hypertensive risk 
and drug responses. Although screening for a single SNP such as rs604723 indicated 
very slight reduction in BP, it is likely that screening for multiple SNPs in the RhoA 
pathway could lead to a more accurate indication of the combination of SNPs along the 
RhoA pathway that may alter BP. Future experiments include: (1) analyzing the 
presence of a combination of SNPs occurring in the genes that regulate RhoA pathway 
in human populations (2) analyzing whether a combination of SNPs affect BP. 
Since blood pressure is regulated by multiple organ systems, a universal anti-
hypertensive treatment suitable for all patients is almost impossible to synthesize. The 
goal of our lab is to find out which SNPs in GRAF3 and other molecules involved in the 
RhoA pathway alter the regulatory function of the pathway, how regulation is achieved, 
and which population subgroups are susceptible to having elevated BP due to elevated 
RhoA activity. Consequently, each population subgroup can be treated in a more 
personalized fashion with an anti-hypertensive treatment that targets RhoA signaling in 
that sub-population, instead of using a more general treatment that might not be very 
effective for every patient. 
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